top of page
Podcast Header (17).png


Download a Transcript of this Episode >>



What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers ten common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options.



Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents.



1. Do all NET patients need to be on lanreotide or octreotide? What’s the difference between lanreotide and octreotide?

2. How do I know what treatments I should be on?

3. My doctor has recommended I take everolimus (afinitor) or CAPTEM. What is the difference and how would I make a decision?

4. My doctor has recommended I take everolimus (afinitor) or PRRT. How would I make that decision?

5. Once I have had PRRT, what would I do next if the tumor progresses?

6. How would I find out what new treatments are on the horizon for NET?

7. Would there be any treatments that negate future choices of treatment options or clinical trials?

8. What does it mean if I have bone mets? (Is my prognosis worse? Does it mean my tumors are getting worse?)

9. If you do not have Somatostatin receptors, should you still have the Gallium DOTATATE scan and if not, what tests/scans do you recommend?

10. Which treatment or other development in this field are you most excited about? What hope might you offer to those living with NET or their loved ones?  



LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment.



bottom of page